Sign Out
Hypersensitivity to natalizumab or to any of the excipients listed in Description.
Progressive multifocal leukoencephalopathy (PML).
Patients with increased risk for opportunistic infections, including immunocompromised patients (including those currently receiving immunosuppressive therapies or those immunocompromised by prior therapies, (see Precautions and Adverse Reactions)).
Combination with other DMTs.
Known active malignancies, except for patients with cutaneous basal cell carcinoma.
Continue with Google